Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Grade 3 Clear Cell Renal Cell Carcinoma	NCIT_C35853	[A clear cell renal cell carcinoma characterized by nucleoli conspicuous and eosinophilic at x 100 magnification. (WHO 1982 /ISUP 2014)]
Grade 4 Clear Cell Renal Cell Carcinoma	NCIT_C35854	[A clear cell renal cell carcinoma characterized by extreme nuclear pleomorphism and/or sarcomatoid and/or rhabdoid differentiation and/or tumor giant cells. (WHO, 1982 /ISUP 2014)]
Squamous Hyperplasia	NCIT_C35855	[A hyperplasia of the squamous epithelial cells.]
Mesonephric Hyperplasia	NCIT_C35856	[A hyperplasia of the mesonephric cells.]
Survivin Positive	NCIT_C131872	[An indication that survivin expression has been detected in a sample.]
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor of Bone	NCIT_C35871	[A spectrum of malignant tumors arising from the bone and characterized morphologically by the presence of small round cells. Ewing sarcoma and peripheral primitive neuroectodermal tumor represent the ends of a spectrum, with Ewing sarcoma lacking evidence of neural differentiation and the markers that characterize the peripheral primitive neuroectodermal tumor. Ewing sarcoma and peripheral primitive neuroectodermal tumor may share cytogenetic abnormalities, proto-oncogene expression, cell culture and immunohistochemical abnormalities. Pain and the presence of a mass are the most common clinical symptoms.]
Malignant Bone Neoplasm	NCIT_C4016	[A primary or metastatic malignant neoplasm affecting the bone or articular cartilage.]
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor	NCIT_C27291	[A spectrum of malignant tumors, affecting mostly males under age 20, characterized morphologically by the presence of small round cells. Ewing sarcoma and peripheral primitive neuroectodermal tumor represent the ends of a spectrum, with Ewing sarcoma lacking evidence of neural differentiation and the markers that characterize the peripheral primitive neuroectodermal tumor. Ewing sarcoma and peripheral primitive neuroectodermal tumor may share cytogenetic abnormalities, proto-oncogene expression, cell culture and immunohistochemical abnormalities. These tumors may occur in the soft tissues or the bones. Pain and the presence of a mass are the most common clinical symptoms.]
Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	NCIT_C131873	[The reemergence of chronic lymphocytic leukemia/small lymphocytic lymphoma after a period of remission.]
Recurrent Hematologic Malignancy	NCIT_C27358	[The reemergence of a hematologic malignancy after a period of remission.]
Recurrent Lymphoproliferative Disorder	NCIT_C147861	[The reemergence of a lymphoproliferative disorder after a period of remission.]
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	NCIT_C27911	[An indolent, mature B-cell neoplasm composed of small, round B-lymphocytes. When the bone marrow and peripheral blood are involved, the term chronic lymphocytic leukemia is used. The term small lymphocytic lymphoma is restricted to cases which do not show leukemic involvement of the bone marrow and peripheral blood.]
Androgen Receptor Antagonist TRC253	NCIT_C131874	[An orally bioavailable androgen receptor (AR) antagonist, with potential antineoplastic activity. Upon oral administration, AR antagonist TRC253 specifically binds to both wild-type and certain mutant forms of AR, thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes, inhibits the expression of genes that regulate prostate cancer cell proliferation, and may lead to an inhibition of growth of tumor cells in which AR is overexpressed and/or mutated. AR is often overexpressed and/or mutated in prostate cancers and plays a key role in proliferation, survival and chemoresistance of tumor cells.]
Androgen Receptor Inhibitor	NCIT_C146993	[Any agent that inhibits the activity of the androgen receptor (AR).]
Negative Regulation of Receptor Activation	NCIT_C40703	[Any intercellular signaling process that reduces the frequency or extent of binding of a cognate ligand to an intracellular or transmembrane receptor to initiate an intracellular response. Receptor inhibition is involved in numerous processes, including metabolism, immune response, sexual development, nervous system function, and regulation of circadian rhythms, mood and behavior.]
Androgen Receptor	NCIT_C17063	[Androgen receptor (919 aa, ~99 kDa) is encoded by the human AR gene. This protein plays a role in the modulation of steroid-dependent gene transcription.]
Translational Repression	NCIT_C29860	[Translational Repression consists of cellular and enzymatic reactions that inhibit the process by which polypeptides are synthesized on ribosomes from information in mRNA transcripts.]
Iatrogenic Kaposi Sarcoma	NCIT_C35873	[A Kaposi sarcoma that develops after organ transplantation or immunosuppressive treatment.]
Kaposi Sarcoma	NCIT_C9087	[A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).]
Therapy-Related Malignant Neoplasm	NCIT_C4969	[The development of a malignant neoplasm in response to medical or surgical treatment, induced by the treatment itself.]